Merck & Co., Inc. (MRK)
NYSE • Healthcare
Last close at November 17, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Merck & Co., Inc. keeps $28 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 2
in 76 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Merck beat expectations on both the top and bottom line in the third fiscal quarter of 2026, based on preliminary results reported October 29, 2026, as revenue of $18.085 billion topped the $17.331 billion estimate (+4.4%) and adjusted EPS of $2.49 topped the $2.09 estimate (+19.1%). Revenue rose ~5% to about $18.1 billion from roughly $17.2 billion a year ago, while adjusted EPS slipped ~4% from $2.58 a year earlier. Profitability held at high levels, with gross margin near 81% and operating margin around 41%, alongside gross profit of roughly $14.7 billion and operating income of about $7.3 billion. For the next period, consensus calls for EPS of $1.90 on revenue of $16.377 billion.
About Merck & Co., Inc.
Merck & Co., Inc., listed on the NYSE under MRK, develops and markets human and animal health products as a global biopharmaceutical company. It operates in the drugmaking business, with FY2025 revenue of $64.9 billion, through a Pharmaceuticals segment focused on medicines and vaccines for people and an Animal Health segment serving veterinary care and livestock markets.
Today's Snapshot
MRK closed 0.8% below yesterday's close, in line with a weaker sector. Merck received positive EU opinions to expand Welireg, its cancer treatment.
Trading Volume
Below 10d avg (7.8M)
7.2M
vs S&P 500 Today
Outperforming Market
+0.60%
Updated: November 17, 2026 at 21:20 UTC
MRK Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$129.44 - $146.20Sell
- RSI (14)44.96Neutral
- Stochastic %K (14, 3, 3)35.68Neutral
- MACD Level (12, 26)0.11Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.